Do analysts prefer HCWB or ALVR?

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 1,019.40%. Given HCW Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe HCW Biologics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HCWB or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. AlloVir's return on equity of -71.03% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% AlloVir N/A -71.03% -61.27%

Is MDXH or HCWB more profitable?

MDxHealth has a net margin of -33.46% compared to HCW Biologics' net margin of -34.73%. MDxHealth's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -23.38% HCW Biologics -34.73% -486.87% -29.19%

Does the media refer more to MDXH or HCWB?

In the previous week, MDxHealth had 7 more articles in the media than HCW Biologics. MarketBeat recorded 11 mentions for MDxHealth and 4 mentions for HCW Biologics. MDxHealth's average media sentiment score of 0.89 beat HCW Biologics' score of 0.58 indicating that MDxHealth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HCWB or NEUP?

In the previous week, HCW Biologics and HCW Biologics both had 4 articles in the media. HCW Biologics' average media sentiment score of 0.58 beat Neuphoria Therapeutics' score of 0.29 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HCWB or CELU more profitable?

HCW Biologics has a net margin of -34.73% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% Celularity -345.45% N/A -77.94%

Does the media refer more to HCWB or ALLR?

In the previous week, Allarity Therapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 5 mentions for Allarity Therapeutics and 4 mentions for HCW Biologics. Allarity Therapeutics' average media sentiment score of 0.62 beat HCW Biologics' score of 0.58 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

HCW Biologics (HCWB) Competitors

$2.68 -0.24 (-8.22%)

Closing price 04:00 PM Eastern

Extended Trading

$2.74 +0.05 (+2.05%)

As of 07:37 PM Eastern

Compare

HCWB vs. ALVR, MDXH, NEUP, CELU, and ALLR

Should you buy HCW Biologics stock or one of its competitors? HCW Biologics's main competitors and comparable companies include AlloVir (ALVR), MDxHealth (MDXH), Neuphoria Therapeutics (NEUP), Celularity (CELU), and Allarity Therapeutics (ALLR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does HCW Biologics compare to AlloVir?

HCW Biologics (NASDAQ:HCWB) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

In the previous week, HCW Biologics had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for HCW Biologics and 0 mentions for AlloVir. HCW Biologics' average media sentiment score of 0.58 beat AlloVir's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Positive
AlloVir	Neutral

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 1,019.40%. Given HCW Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe HCW Biologics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

HCW Biologics has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

AlloVir has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. AlloVir's return on equity of -71.03% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
AlloVir	N/A	-71.03%	-61.27%

HCW Biologics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	85.76	-$7.96M	-$56.75	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

HCW Biologics beats AlloVir on 10 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

MDxHealth has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market.

MDxHealth currently has a consensus target price of $2.83, indicating a potential upside of 250.66%. HCW Biologics has a consensus target price of $30.00, indicating a potential upside of 1,019.40%. Given HCW Biologics' higher possible upside, analysts plainly believe HCW Biologics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MDxHealth has a net margin of -33.46% compared to HCW Biologics' net margin of -34.73%. MDxHealth's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
HCW Biologics	-34.73%	-486.87%	-29.19%

3.0% of HCW Biologics shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

HCW Biologics has lower revenue, but higher earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
HCW Biologics	$50K	85.76	-$7.96M	-$56.75	N/A

In the previous week, MDxHealth had 7 more articles in the media than HCW Biologics. MarketBeat recorded 11 mentions for MDxHealth and 4 mentions for HCW Biologics. MDxHealth's average media sentiment score of 0.89 beat HCW Biologics' score of 0.58 indicating that MDxHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MDxHealth beats HCW Biologics on 9 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to Neuphoria Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, HCW Biologics and HCW Biologics both had 4 articles in the media. HCW Biologics' average media sentiment score of 0.58 beat Neuphoria Therapeutics' score of 0.29 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HCW Biologics currently has a consensus target price of $30.00, indicating a potential upside of 1,019.40%. Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 442.64%. Given HCW Biologics' higher possible upside, research analysts plainly believe HCW Biologics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuphoria Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Neuphoria Therapeutics' return on equity of -76.93% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

HCW Biologics has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than HCW Biologics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	85.76	-$7.96M	-$56.75	N/A
Neuphoria Therapeutics	$15.65M	1.34	-$370K	-$11.06	N/A

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

HCW Biologics beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to Celularity?

HCW Biologics (NASDAQ:HCWB) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

HCW Biologics has a net margin of -34.73% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Celularity	-345.45%	N/A	-77.94%

HCW Biologics has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Celularity has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, HCW Biologics had 3 more articles in the media than Celularity. MarketBeat recorded 4 mentions for HCW Biologics and 1 mentions for Celularity. Celularity's average media sentiment score of 1.89 beat HCW Biologics' score of 0.58 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
HCW Biologics	Positive
Celularity	Very Positive

HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 1,019.40%. Celularity has a consensus price target of $6.00, indicating a potential upside of 762.32%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HCW Biologics has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	85.76	-$7.96M	-$56.75	N/A
Celularity	$26.55M	0.76	-$91.72M	-$3.33	N/A

Summary

HCW Biologics beats Celularity on 8 of the 14 factors compared between the two stocks.

How does HCW Biologics compare to Allarity Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

HCW Biologics has higher earnings, but lower revenue than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	85.76	-$7.96M	-$56.75	N/A
Allarity Therapeutics	$320K	68.11	-$11.23M	-$0.72	N/A

Allarity Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Allarity Therapeutics' return on equity of -109.94% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Allarity Therapeutics	N/A	-109.94%	-47.27%

HCW Biologics has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

HCW Biologics currently has a consensus price target of $30.00, suggesting a potential upside of 1,019.40%. Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 648.18%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Allarity Therapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 5 mentions for Allarity Therapeutics and 4 mentions for HCW Biologics. Allarity Therapeutics' average media sentiment score of 0.62 beat HCW Biologics' score of 0.58 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

HCW Biologics and Allarity Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.67M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.05	10.67	269.06	25.28
Price / Sales	85.76	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.53	16.78	12.91	6.24
Net Income	-$7.96M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-21.41%	1.74%	1.12%	1.07%
1 Month Performance	-40.44%	1.60%	1.79%	1.03%
1 Year Performance	-89.71%	56.43%	67.69%	20.77%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	3.9221 of 5 stars	$2.68 -8.2%	$30.00 +1,019.4%	-89.2%	$4.67M	$50K	N/A	40	News Coverage Earnings Report
ALVR AlloVir	N/A	$4.32 +6.7%	N/A	+58.2%	$21.79M	N/A	N/A	110	High Trading Volume
MDXH MDxHealth	2.4945 of 5 stars	$0.43 -2.0%	$3.50 +708.3%	-83.2%	$21.43M	$107.88M	N/A	300	Trending News Earnings Report Analyst Forecast Gap Up Trading Halted
NEUP Neuphoria Therapeutics	2.3739 of 5 stars	$3.95 +1.5%	$21.00 +431.6%	-51.8%	$21.33M	$15.65M	N/A	N/A	Short Interest Increase
CELU Celularity	2.5985 of 5 stars	$0.73 +4.4%	$6.00 +717.2%	-80.5%	$21.26M	$26.55M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. ALVR, MDXH, NEUP, CELU, and ALLR

How does HCW Biologics compare to AlloVir?

Summary

How does HCW Biologics compare to MDxHealth?

Summary

How does HCW Biologics compare to Neuphoria Therapeutics?

Summary

How does HCW Biologics compare to Celularity?

Summary

How does HCW Biologics compare to Allarity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. ALVR, MDXH, NEUP, CELU, and ALLR

How does HCW Biologics compare to AlloVir?

Does the media refer more to HCWB or ALVR?

Do analysts prefer HCWB or ALVR?

Do institutionals & insiders have more ownership in HCWB or ALVR?

Which has more volatility & risk, HCWB or ALVR?

Is HCWB or ALVR more profitable?

Which has better valuation and earnings, HCWB or ALVR?

Summary

How does HCW Biologics compare to MDxHealth?

Which has more volatility & risk, MDXH or HCWB?

Do analysts recommend MDXH or HCWB?

Is MDXH or HCWB more profitable?

Do insiders and institutionals hold more shares of MDXH or HCWB?

Which has higher earnings & valuation, MDXH or HCWB?

Does the media refer more to MDXH or HCWB?

Summary

How does HCW Biologics compare to Neuphoria Therapeutics?

Does the media refer more to HCWB or NEUP?

Do analysts rate HCWB or NEUP?

Is HCWB or NEUP more profitable?

Which has more risk & volatility, HCWB or NEUP?

Which has stronger earnings & valuation, HCWB or NEUP?

Do institutionals & insiders hold more shares of HCWB or NEUP?

Summary

How does HCW Biologics compare to Celularity?

Do institutionals and insiders hold more shares of HCWB or CELU?

Is HCWB or CELU more profitable?

Which has more volatility & risk, HCWB or CELU?

Does the media prefer HCWB or CELU?

Do analysts rate HCWB or CELU?

Which has better earnings and valuation, HCWB or CELU?

Summary

How does HCW Biologics compare to Allarity Therapeutics?

Which has better earnings & valuation, HCWB or ALLR?

Is HCWB or ALLR more profitable?

Which has more volatility & risk, HCWB or ALLR?

Do analysts prefer HCWB or ALLR?

Does the media refer more to HCWB or ALLR?

Do insiders and institutionals hold more shares of HCWB or ALLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools